Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regulatory approval in the U.S. Positive Phase 3 results from Sagimet's Chinese partner, Ascletis, suggest promising efficacy, raising hopes for similar outcomes in the U.S. With an estimated 10 million Americans affected by moderate to severe acne, denifanstat could address a significant market if approved.
Sagimet's advancement of denifanstat in a Phase 3 acne trial is the subject, with Pluang's Health sector market data as context. As of Oct 22, 2026 23:11 WIB, out of 150 priced Health-sector US stocks tradable on Pluang, 92 rose and 56 fell today. Notable movers include Natera Inc. Common Stock (NTRA) at USD 392.52 with a 1-day change of -5.05% and a typical hold time of 7 days, Smith & Nephew plc (SNN) at USD 30.64 with a 1-day change of +4.84% and 100% sell order activity, and GeneDx Holdings Corp (WGS) at USD 65.71 with a 1-day change of -4.69% and 100% buy order activity.
Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...
RingCentral will announce its Q3 2026 earnings on October 22, with analysts forecasting earnings per share between $1.27 and $1.28 and revenue around $667 million. This represents a 12.4% increase in earnings and 4.4% growth in revenue compared to th...
Freddie Mac reported that the average 30-year fixed mortgage rate fell to 7.32% as of October 22, 2026, down from 7.40% the previous week. This decline offers some relief to prospective homebuyers facing higher borrowing costs compared to last year, ...
Canada's 5G device market is forecasted to expand from USD 10 billion in 2026 to USD 15.2 billion by 2031, growing at 8.7% annually. Growth is fueled by mid-band spectrum deployment, federal connectivity programs, and rising enterprise adoption of ad...
Alaska Air Group reported a $147 million loss in Q3 2026, driven by higher-than-expected fuel costs despite strong revenue growth. The company expects an even larger loss in Q4 as fuel expenses continue to rise. Despite these challenges, BMO Capital ...
